CombiGene and Cell and Gene Therapy Catapult sign agreement to develop manufacturing process for novel gene therapy to treat epilepsy

Jan 12, 2018

Collaboration between Cell and Gene Therapy Catapult (CGT Catapult) and Swedish gene therapy company CombiGene will take a unique therapy one step closer to helping sufferers of hard to treat epilepsy.
Read more >>

Nyheter och rapporter

Ingeneious #2 2018, News from CombiGene 4 June, 2018
EU allocates EUR 3.6 million in funding for development of CombiGene’s cuttingedge gene therapy 15 May, 2018
Interim Report January-March 2018 3 May, 2018
Annual Report 2017 2 May, 2018
CombiGene: New issue registered 9 April, 2018
Notice of Annual General Meeting of shareholders in CombiGene AB (publ) 29 March, 2018
Ingeneious #1 2018, News from CombiGene 15 March, 2018

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"